InMed Pharmaceuticals (INM) has released an update.
InMed Pharmaceuticals has made significant strides in its pharmaceutical programs, particularly with its Alzheimer’s treatment candidate, INM-901, showing promising preclinical data. The company also executed a reverse stock split to ensure continued compliance with Nasdaq listing requirements, reflecting its commitment to enhancing shareholder value.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.